In after-hours trade Tuesday, Supernus Pharmaceuticals (SUPN) shares soared more than 24% percent to $27.99, following the firm revealed promising findings from a trial of its new treatment for attention deficit hyperactivity disorder, or ADHD. Supernus reported Tuesday afternoon that its intended goal was met in a phase 3 trial of the medication, known as SPN-812, in adults.
The Food and Drug Administration is actively reviewing the drug for use in children aged 6 to 17, and once it is approved by the FDA, Supernus plans to ask that the drug be considered for adults as well.
#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024
We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.
Learn all about it in this brand new FREE online report.
Shares surged more than 40% as trades resumed after the end of after-hours trading Tuesday afternoon, but gradually declined to around 20 percentsurge by the end of the extended session.